ProCE Banner Events

Share

APPlexus Hot Topics 2024: Updates in Oncology and Hematology 

APPlexus is an initiative designed to address educational needs specific to advanced practice providers who care for patients with cancer. This meeting will navigate insights and updates across several cancer types and deliver innovative, real-time education to nurse practitioners and physician associates worldwide. Our mission is to bridge knowledge gaps, untangle controversies, and spotlight pivotal data in a digestible and engaging format.

Nurse Practitioners: 3.00 Nursing contact hours, includes 3.00 hour of pharmacotherapy credit

Registered Nurses: 2.00 Nursing contact hours

Physician Assistants/Physician Associates: 2.00 AAPA Category 1 CME credits

Physician Assistants/Physician Associates: 3.00 AAPA Category 1 CME credits

Credits Available

Attendees can earn up to 5.0 credits.

Who Should Attend

This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.

Time and location

Saturday, May 18, 2024

8:00 AM - 1:20 PM Eastern Time (ET)

Virtual

Faculty
Sandra E. Kurtin, PhD, ANP-BC, FAPO

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
The University of Arizona
Tucson, Arizona

Caroline Kuhlman, MSN, APRN-BC

Nurse Practitioner, Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital
Boston, Massachusetts

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Sherry Adkins, MSN, ANP-C, FAAN

Advanced Practice Provider Supervisor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Colleen H. Tetzlaff, MHS, PA-C

Advanced Practice Provider
Physician Assistant
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Agenda

8:00 AM – 8:05 AM ET: Welcome and Opening Remarks 

8:05 AM – 9:05 AM ET: Advances in Targeted Therapeutics for Biliary Tract Cancer

9:05 AM – 10:05 AM ET: BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment and Enhancing Access

10:05 AM – 11:05 AM ET: Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies

11:05 AM – 11:10 AM ET: Break

11:10 AM – 12:10 PM ET: Next-Generation Care for Patients With Bladder Cancer

12:10 PM – 1:10 PM ET: Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL

1:10 PM – 1:15 PM ET: Summary and Closing Remarks

CME/CE Info

Target Audience
This program is intended for nurse practitioners, nurses, physician associates, and other healthcare professionals who care for patients with cancer.


Advances in Targeted Therapeutics for Biliary Tract Cancer

Goal Statement
To improve the knowledge, confidence, and skills of NPs/PAs who care for patients with biliary tract cancer on the latest updates in guideline-directed evidence-based medicine, therapeutic management, and strategies to improve health equity, ultimately improving clinical outcomes for their patients.

Learning Objectives

  • Evaluate current and emerging evidence for use of immune checkpoint inhibitors or other targeted therapies in the treatment of patients with BTC
  • Identify and manage signs and symptoms of irAEs in patients treated with immune checkpoint inhibitors for BTC
  • Educate patients with BTC and their caregivers about potential enrollment on clinical trials investigating immune checkpoint inhibitors and other targeted treatment options or combinations

BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with multiple myeloma.

Learning Objectives

  • Understand the underlying principles and motivations behind targeting BCMA- and CD38-targeted therapies to provide comprehensive and empathetic guidance to patients exploring this therapeutic avenue
  • Evaluate the proven effectiveness and safety of BCMA- and CD38-targeted interventions, facilitating informed discussions and expectations management with patients
  • Recognize individual patient needs and disease-specific indicators when suggesting BCMA- and CD38-targeted treatment options, ensuring personalized and optimal care recommendations
  • Navigate the practicalities of antibody and immunotherapy in multiple myeloma care, focusing on dosing, scheduling, specialized referrals, patient education, counseling, and managing unique treatment-related side effects

Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to safely and effectively integrate bispecific antibody therapy into practice to optimize patient outcomes. 

Learning Objectives

  • Evaluate emerging safety and efficacy data on bispecific antibody therapeutics in the treatment of patients with hematologic malignancies
  • Employ strategies to care for patients with hematologic malignancies treated with bispecific antibody–based therapeutic strategies, taking into consideration current indications, safety profiles, administration considerations, and expert guidance
  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with hematologic malignancies
  • Provide equitable and inclusive patient communication and counseling for patients receiving bispecific antibody therapy

Next-Generation Care for Patients With Bladder Cancer

Goal Statement
To improve the knowledge, confidence, and skills of NPs/PAs who care for patients with bladder cancer on the latest updates in guideline-directed and evidence-based medicine, therapeutic management, and strategies to improve health equity, ultimately improving clinical outcomes for their patients.

Learning Objectives

  • Evaluate current and emerging evidence for targeted and immunotherapies in bladder cancer—including non-muscle-invasive, muscle-invasive, locally advanced, and metastatic disease—considering impact of toxicity profiles, prognostic variables, comorbidities, treatment duration, and patient preference
  • Plan optimal medical and pharmacologic management strategies for patients with bladder cancer on immune checkpoint inhibitors, targeted therapies, chemotherapy, or gene therapy to manage treatment-related adverse events
  • Counsel individual patients with bladder cancer on the potential for enrollment on ongoing clinical trials investigating novel therapies or treatment combinations

Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Bladder Cancer.

Learning Objectives

  • Describe to patients the differences between covalent and noncovalent BTKi in terms of molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, and efficacy and their respective impact on clinical practice
  • Evaluate the available clinical evidence and guideline recommendations on noncovalent BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL
  • Manage adverse events associated with noncovalent BTKi-based therapies considering safety profiles unique to each agent and regimen
  • Identify patients with R/R MCL and R/R SLL/SLL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations 

Accreditation

BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access
Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours.

  • BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access: 1.0
  • Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies: 1.0

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

  • BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access: 1.0
  • Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies: 1.0

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Advances in Targeted Therapeutics for Biliary Tract Cancer
Next-Generation Care for Patients With Bladder Cancer
Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.0 contact hours, including 3.0 hours of pharmacotherapy credit.

  • Advanced in Targeted Therapeutics for Biliary Tract Cancer: 1.0
  • Next-Generation Care for Patients With Bladder Cancer: 1.0
  • Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL: 1.0

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • Advanced in Targeted Therapeutics for Biliary Tract Cancer: 1.0
  • Next-Generation Care for Patients With Bladder Cancer: 1.0
  • Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL: 1.0

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 3.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Advanced in Targeted Therapeutics for Biliary Tract Cancer: 1.0
  • Next-Generation Care for Patients With Bladder Cancer: 1.0
  • Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL: 1.0

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

 

Acknowledgement

Advances in Targeted Therapeutics for Biliary Tract Cancer

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access

Provided by Clinical Care Options, LLC in partnership with Partners for Advancing Clinical Education (PACE) and Practicing Clinicians Exchange, LLC.

Supported by an educational grant from Sanofi Genzyme.

Redefining Precision Therapeutics in Hematologic Malignancies: Current Practice and Next Questions on Bispecific Antibodies

Provided by Clinical Care Options, LLC in partnership with Partners for Advancing Clinical Education (PACE) and Practicing Clinicians Exchange, LLC.

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC

Next-Generation Care for Patients With Bladder Cancer

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by an educational grant from Merck Sharp & Dohme LLC.

Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by an educational grant from Merck Sharp & Dohme LLC.

 

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.